tiprankstipranks
Trending News
More News >
Galera Therapeutics (GRTX)
OTHER OTC:GRTX
US Market
Advertisement

Galera Therapeutics (GRTX) Price & Analysis

Compare
260 Followers

GRTX Stock Chart & Stats


Galera Therapeutics News

GRTX FAQ

What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $0.02 and its highest was $0.08 in the past 12 months.
    What is Galera Therapeutics’s market cap?
    Galera Therapeutics’s market cap is $1.71M.
      When is Galera Therapeutics’s upcoming earnings report date?
      Galera Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is 10 days ago.
        How were Galera Therapeutics’s earnings last quarter?
        Galera Therapeutics released its earnings results on May 19, 2025. The company reported -$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.016.
          Is Galera Therapeutics overvalued?
          According to Wall Street analysts Galera Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Galera Therapeutics pay dividends?
            Galera Therapeutics does not currently pay dividends.
            What is Galera Therapeutics’s EPS estimate?
            Galera Therapeutics’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Galera Therapeutics have?
            Galera Therapeutics has 75,462,390 shares outstanding.
              What happened to Galera Therapeutics’s price movement after its last earnings report?
              Galera Therapeutics reported an EPS of -$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Galera Therapeutics?
                Currently, no hedge funds are holding shares in GRTX

                Company Description

                Galera Therapeutics

                Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

                Galera Therapeutics (GRTX) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                TNF Pharmaceuticals
                Salarius Pharmaceuticals
                Scinai Immunotherapeutics
                Evaxion Biotech
                Onconetix

                Ownership Overview

                10.50%<0.01%3.90%85.60%
                10.50% Insiders
                3.90% Other Institutional Investors
                85.60% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis